Phesgo (Pertuzumab, trastuzumab, and hyaluronidase-zzxf) for Breast Cancer

Overview
Phesgo is a combination prescription drug approved by the U.S. Food and Drug Administration (FDA) for use with chemotherapy to treat adults with early-stage HER-2 positive breast cancer. Phesgo is also approved for use with docetaxel to treat people with HER-2 positive metastatic breast cancer who haven’t received previous chemotherapy or anti-HER2 therapy. Phesgo is also referred to by the drug names of its components: pertuzumab, trastuzumab, and hyaluronidase-zzxf.

Phesgo is used as a targeted therapy for breast cancer. Phesgo is a combination of drugs belonging to the class of drugs called HER2/neu receptor antagonists. Phesgo is believed to work by binding to cancer cells, stopping cell growth, and causing cell death.

How do I take it?
Prescribing information states that Phesgo is given as a subcutaneous (under your skin) injection by a healthcare professional. Phesgo is usually given in a health clinic or doctor’s office. It should be administered according to the frequency specified by the physician.

Phesgo is available only as a subcutaneous injection.

Side effects
The FDA-approved label for Phesgo lists common side effects including hair loss, nausea, diarrhea, anemia (low red blood cell count), neutropenia (low white blood cell count), rash, nerve problems, and asthenia (general weakness).

Rare but serious side effects listed for Phesgo include very low white blood cell counts and severe hypersensitivity reactions (exaggerated immune responses to antigens or allergens).

For more details about this treatment, visit:

Phesgo — Genentech
https://www.phesgo-hcp.com/

Phesgo — Breastcancer.org
https://www.breastcancer.org/treatment/targeted...